Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987 - 2008

Tidsskrift for den Norske Laegeforening

Volumn 133, Issue 16, 2013, Pages 1704-1709

  Smeland, Knut Bjøro ^a   Kiserud, Cecilie E ^a   Lauritzsen, Grete F ^a   Blystad, Anne Kirsti ^a   Fagerli, Unn Merete ^b,c   Fluge, Øystein ^d   Fosså, Alexander ^a   Hammerstrøm, Jens ^b   Kolstad, Arne ^a   Loge, Jon Håvard ^a,e   Maisenhølder, Martin ^f   Østenstad, Bjørn ^a   Kvaløy, Stein ^a,e   Holte, Harald ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f not available   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; AUTOTRANSPLANTATION; EPIDEMIOLOGY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NORWAY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UTILIZATION; YOUNG ADULT; ARTICLE; STATISTICS; UTILIZATION REVIEW;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NORWAY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84887371867     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.13.0243     Document Type: Article

References (21)

1. Smeland KB, Kiserud CE, Lauritzen GF et al. Høydosebehandling med autolog stamcellestøtte ved lymfom - fra utprøvende til standard behandling. Tidsskr Nor Legeforen 2013; 133: 1735 - 9.
2. Høydosebehandling med autolog stamcellestøtte ved maligne lidelser. Helsedirektoratets utredningsserie 1-951995. Oslo: Statens helsetilsyn, 1995.
3. Hammerstrøm J, Aasland IL, Telhaug R et al. Høydosebehandling med stamcellestøtte i Midt-Norge. Tidsskr Nor Lægeforen 2004; 124: 2498 - 500.
4. Liseth K, Abrahamsen JF, Ekanger R et al. Overlevelse etter høydosebehandling med autolog stamcellestøtte. Tidsskr Nor Lægeforen 2004; 124: 1374 - 5.
5. Cancer in Norway 2010 - cancer incidence, mortality, survival and prevalence in Norway 2012. Oslo: Kreftregisteret, 2012.
6. Griffin MM, Morley N. Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials. Expert Opin Biol Ther 2013; 13: 803 - 11.
7. Smeland S, Blystad AK, Kvaløy SO et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15: 1072 - 8.
8. Jantunen E, Itälä M, Lehtinen T et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006; 76: 245 - 50.
9. Passweg JR, Baldomero H, Gratwohl A et al. The EBMT activity survey: 1990 - 2010. Bone Marrow Transplant 2012; 47: 906 - 23.
10. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051 - 4.
11. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with highdose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065 - 71.
12. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540 - 5.
13. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progressionfree survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677 - 84.
14. Vanderwalde AM, Sun CL, Laddaran L et al. Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. Leukemia 2013; 27: 1139 - 45.
15. Sweetenham JW, Santini G, Qian W et al. Highdose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/ maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001; 19: 2927 - 36.
16. Schaaf M, Reiser M, Borchmann P et al. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev 2012; 1: CD007678.
17. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne lymfomer nr. 987-82-8081-113-4/2012. Oslo: Norsk lymfomgruppe, 2012.
18. Abrahamsen AF, Loge JH, Hannisdal E et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol 1999; 38: 511 - 5.
19. Kiserud CE, Fosså A, Bjøro T et al. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer 2009; 100: 455 - 63.
20. Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J 2009; 15: 164 - 8.
21. Wethal T, Lund MB, Edvardsen T et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer 2009; 101: 575 - 81.